Tissue-specific patterns of microRNA (miRNA) expression contribute to organogenesis during embryonic development. Using the embryonic chicken gonads as a model for vertebrate gonadogenesis, we previously reported that miRNAs are expressed in a sexually dimorphic manner during gonadal sex differentiation. Being male biased, we hypothesised that upregulation of microRNA 202* (MIR202*) is characteristic of testicular differentiation. To address this hypothesis, we used estrogen modulation to induce gonadal sex reversal in embryonic chicken gonads and analyzed changes in MIR202* expression. In ovo injection of estradiol-17beta at Embryonic Day 4.5 (E4.5) caused feminization of male gonads at E9.5 and reduced MIR202* expression to female levels. Female gonads treated at E3.5 with an aromatase inhibitor, which blocks estrogen synthesis, were masculinized by E9.5, and MIR202* expression was increased. Reduced MIR202* expression correlated with reduced expression of the testis-associated genes DMRT1 and SOX9, and up-regulation of ovary-associated genes FOXL2 and CYP19A1 (aromatase). Increased MIR202* expression correlated with down-regulation of FOXL2 and aromatase and up-regulation of DMRT1 and SOX9. These results confirm that up-regulation of MIR202* coincides with testicular differentiation in embryonic chicken gonads.
INTRODUCTION
In vertebrate embryos, the gonads intitally develop as bipotential organs before undergoing sexual differentiation (testes in males, ovaries in females). Therefore, gonadal sex differentiation provides an ideal model for studying the genetic regulation of organogenesis. In the chicken (Gallus domesticus), the embryonic gonads differentiate into either bilateral testes in males or an asymmetric left ovary in females [1] .
Sexual dimorphism in chicken embryonic gonads is first evident histologically at Embryonic Day 6.5 (E6.5) of the 21-day incubation period. From this time, seminiferous (testis) cords containing Sertoli cells and primordial germ cells (PGCs) form in male gonads. In females, the left gonad develops into a functional ovary, with a thickened outer cortex that contains PGCs, while the underlying medulla undergoes vacuolation. The right female gonad fails to proliferate a cortex and undergoes regression [1] .
The direction of gonadal sex differentiation in higher vertebrates (birds and mammals), is determined by the the inheritance of sex chromosomes. In mammals (female: XX; male: XY), the sex-determining region Y (SRY) gene acts as the primary testis-determining factor [2] . The Z and W sex chromosomes of birds (male: ZZ; female: ZW) are are not homologous to the mammalian X and Y, and SRY is absent. Instead, the conserved Z-linked gene, double-sex and mab-3-related transcription factor 1 (DMRT1), acts as a major regulator of testicular development via a dosage mechanism [3] . In the chicken, DMRT1 expression is higher in male (ZZ) gonads [4, 5] and knockdown of DMRT1 in ovo, disrupts expression of the testis-associated gene SRY (sexdetermining region Y)-box 9 (SOX9), and up-regulates the ovary-associated genes, Forkhead box L2 (FOXL2) and cytochrome P450, family 19, subfamily A, polypeptide 1, (CYP19A1; herein referred to as aromatase) [3] . However, the regulatory mechanisms that coordinate these testicular and ovarian-determining pathways in the chicken are poorly understood.
The female sex hormone estrogen (estradiol-17b; herein abbreviated as E2) is required for ovarian differentiation in the chicken embryo [6, 7] . Genes encoding the steroidogenic enzymes aromatase and hydroxysteroid (17-beta) dehydrogenase 1 (HSD17B1) are expressed in the embryonic gonads in a female-specific manner from E6.0 on [8] [9] [10] . These enzymes are required specifically for estrogen biosynthesis in the developing ovary [11] . Inhibiting the activity of aromatase is sufficient to cause female-to-male gonadal sex reversal [6, 7, 12, 13] . Conversely, treatment of male embryos with exogenous estrogen prior to the onset of gonadal differentiation is able to feminize development of the male left gonad, resulting ovary, or ovo-testis formation [8, 14, 15] .
Aside from protein-coding genes and steroid hormones, microRNAs may also be involved in regulating embryonic testis versus ovary development [16, 17] . MicroRNAs (miRNAs) are small (18-24 nt) noncoding RNAs that act as negative regulators of gene expression [18, 19] . They play important roles in a variety of developmental processes in animals [20] . In the reproductive system, miRNAs may be involved in regulating spermatogenesis [21, 22] . Conditional knockout of the key Dicer enzyme in mouse gonads also highlights a requirement for miRNAs in maintaining Sertoli cell functions [23, 24] and cell survival [25] during neonatal and postnatal testis development. Endogenous miRNA profiles differ between postnatal testes and ovaries in mice [26] [27] [28] . These findings suggest that miRNAs may be involved in regulating postnatal testicular and ovarian functions.
We have previously shown that miRNAs are expressed in a sexually dimorphic manner in embryonic chicken gonads at three developmental stages spanning sexual differentiation [16] . More recently, Takada et al. have also demonstrated sexually dimorphic miRNA expression at 13.5 days postcoitum (dpc) in embryonic mouse gonads [29] . Their findings indicate that mouse MIR29B (or mmu-miR-29b) may promote the development of female primordial germ cells (PGCs) by downregulating the expression of the DNA methyltransferases Dnmt3a and Dnmt3b [29] . Further, Huang and colleagues have characterized a novel chicken miRNA, MIR363, that it is expressed in a female-biased manner at E6.5 in embryonic chicken gonads [30] . Together, these findings suggest that miRNAs are likely to be involved in regulating the embryonic gonadal sex differentiation. In our previous study, we showed that MIR202* expression is male biased during testicular development in embryonic chicken gonads [16] . This indicated that MIR202* may play a role in regulating embryonic testis development.
To extend our previous studies, we sought to confirm that up-regulation of MIR202* is specifically associated with testicular differentiation using an experimental model. Modulating estrogen levels in the embryonic chicken gonads prior to the onset of sexual differentiation is known to induce gonadal sex reversal [6, 9, 12-15, 31, 32] . Therefore, we used estrogen modulation to feminize male (ZZ) gonads and masculinize female (ZW) gonads in order to study the association between male-biased MIR202* expression and gonadal sex differentiation. Changes in MIR202* expression were analyzed in E9.5 control gonads versus male and female gonads treated with either estrogen (estradiol-17b, or E2) or an aromatase inhibitor (AI; Fadrozole) that blocks estrogen synthesis. The results confirmed that up-regulation of MIR202* expression specifically coincides with testicular differentiation in the chicken embryo.
MATERIALS AND METHODS

Gonad Tissue Collection
All experiments involving chicken embryos in ovo were carried out in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (7th ed., 2004) and according to institutional animal ethics guidelines (Murdoch Childrens Research Institute and CSIRO Australian Animal Health Laboratory). Eggs from commercial chicken lines were sourced from Bartter Enterprises Pty Limited (Ross 308) and research poultry farm (Rhode Island Red/Australop cross). Eggs were incubated at 388C. Gonads or urogenital systems (UGS, gonads, and mesonephric kidneys) were dissected from chicken embryos at E9.5 in Petri dishes (BD Falcon) containing diethylpyrocarbonate-treated PBS. For immunofluorescence or whole-mount in situ hybridization (WISH), UGS tissues were fixed in 4% paraformaldehyde/ PBS (PFA/PBS; Merck). Gonads taken for RNA were separated from embryonic kidneys, immediately frozen in 0.5 ml RNase-free tubes (Ambion) on dry ice, and stored at À808C during sexing.
Injection of Estradiol-17b and AI Fadrozole In Ovo
All in ovo injections were performed under sterile conditions using autoclave-sterilized instruments and sterile single-use 26G1/2 needles and 1-cc/ml tuberculin syringes (Terumo Medical Corporation). The injection time points represent stages of bipotential gonadal development and were chosen on the basis of existing protcols [6-8, 12, 14, 15, 32] . Injections were made directly into the albumen at the pointed end of the egg. Estradiol-17b (herein refered to as E2; catalog no. E1024; Sigma-Aldrich) was prepared at 1-mg/ml concentration in sterile 95% ethanol/ PBS. A single dose of 0.1 ml E2 in 100 ll was administered per egg at E4.5. Fadrozole (Novartis) was used as the AI. Stock solution was prepared at 10-mg/ml concentration in sterile PBS. A single dose of 1 mg AI in 100 ll was administered per egg at E3.5. Controls were injected with 100 ll of either 95% ethanol/PBS for estradiol for E2 experiments or 100 ll of PBS for AI experiments. Injected eggs were heat sealed with Parafilm M (Pechiney Plastic Packaging) and reincubated at 388C until E9.5.
Embryo Sexing
All embryos were sexed at E9.5 macroscopically, by gonad morphology, and by sexing PCR. For macroscopic sexing, females were distinguished by asymmetric development of a large, flattened left ovary and visibly smaller right gonad, while males were distinguished by the presence of cylindrical, symmetrical gonads, as described previously [1] . For the sexing PCR, a piece of leg tissue from each embryo was collected in 30 ll of PCR digestion [16] . Sexing PCR was carried out using the primers and methods described by Clinton et al. [33] . Reactions were prepared in final volume of 20 ll, using GoTaq Green Master Mix (Promega) according to the manufacturer's instructions. PCRs were run in a Mastercycler S thermal cycler (Eppendorf). Products were run on 1.5% 13 Tris-Borate EDTA (TBE) or Tris-Acetate EDTA (TAE) agarose gels.
Analysis of Sex-Marker Expression by Immunofluorescence
Urogenital systems were dissected from E9.5 embryos and fixed at room temperature for 15-20 min in 4% PFA/PBS at room temperature, then in 30% sucrose/PBS at 48C overnight. Immunofluorescence was performed as described previously [3] . Briefly, tissues were frozen in TissueTek O.C.T (Sakura) on dry ice/ethanol slurry and stored at À808C. Serial sections were cut at 5 lm on a cryostat (À178C; Leica Microsystems) and rehydrated in PBS. Sections were then treated with 1% Triton X-100 (Merck) in PBS for 10 min at room temperature, then blocked in 5% BSA/PBS for at least 30 min. Primary antibody solution comprised 1% BSA and 0.1% Triton X-100. Primary antibodies used were rabbit-anti-chicken aromatase IgG (1:6000), rabbit-antichicken vasa homolog (CVH) IgG (1:6000), rabbit-anti-chicken DMRT1 IgG (1:6000) [3, 32] , and mouse-anti-chicken fibronectin 1 (FN1) (1:1500; Serotec). Secondary antibodies conjugated with Alexa fluor dyes (Invitrogen)-donkeyanti-rabbit IgG-Alexa488 (1:1000) and donkey-anti-mouse IgG-Alexa594 (1:1000) [3] -were then hybridized at room temperature for 1 h in 1% BSA/ PBS. Sections were washed and treated with 4 0 ,6-diamidino-2-phenylindole (1 mg/ml; Sigma-Aldrich) for 5 min in MilliQ-water and mounted for imaging using aqueous fluorescent mounting medium (DAKO). Images were captured at 2003 magnification using a Leica DMLB fluorescence microscope and a DC300F camera (Leica Microsystems).
Gonad WISH
WISH analysis for MIR202* expression in E9.5 chick embryonic urogenital systems (UGS) was performed using LNA probes at 468C hybridization temperature, as described previously [16] (see also the section ''Primers and Probes'' below for details of LNA probes). Between 2 and 6 UGS were analyzed for each sex per experiment. Experiments were repeated for WISH analysis at least twice. Results were analyzed after overnight development of WISH staining in NBT/BCIP color reagents. Images of whole-mount gonads were captured using a Leica MZ16F stereomicroscope fitted with DFC290 color camera (Leica Microsystems) and Photoshop CS2 Software (Adobe).
RNA Extractions
All RNA extractions were carried out using Trizol Reagent (Invitrogen) according to the manufacturer's instructions. Glycogen (10 lg; Invitrogen) was added to the aqueous phase, and 80% ethanol was used for the wash step to enhance precipitation of small RNAs. Gonads frozen at À808C were thawed in Trizol and pooled for RNA extraction according to sex. Generally, gonads were pooled in groups of two to three gonad pairs for RNA extraction (left and right together). RNA pellets were resuspended in 10-20 ll of nuclease-free water (NFwater; Promega). Where necessary, RNA sample volumes were concentrated using vacuum centrifugation (SpeedVac; Thermo-Scientific). Prior to reverse transcription, RNA samples were treated with RQ1 DNase (Promega) according to the manufacturer's instructions. RNA and cDNA concentrations were determined using a NanoDrop 1000 spectrophotometer (ThermoScientific). All RNA samples were stored at À808C.
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Sex-Marker Gene Expression Analysis by Quantitative Reverse-Transcriptase Polymerase Chain Reaction
Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) for sex-marker gene expression was performed using cDNA reverse transcribed from 1 lg of total RNA using random hexamers and Superscript III reverse transcriptase (Superscript III First-Strand Synthesis System Supermix; Invitrogen). Roche Universal Probe Library (UPL) and LightCycler480 system (Roche Applied Science) were used for quantitative analysis. Reaction mixes contained 1 ll cDNA at 1:5 dilution, 0.1 ll of UPL probe (Roche Applied Science), 3 ll of 1-lM primer mix (left and right), and 5 ll of LC480 23 Master Mix (Roche Applied Science). Cycle settings for LC480 were 948C, 10 min; 45 cycles of 948C, 10 sec; 608C, 10 sec; and 728C, 10 sec. Relative expression was calculated by the delta-delta Ct method using Microsoft Excel (Microsoft Corporation). Hypoxanthine phosphoribosyltransferase 1 (HPRT) was used as a reference control gene. Changes in gene expression were analyzed statistically by the Student t-test using Prism5 software (GraphPad Software Inc.).
MIR202* Expression Analysis by qRT-PCR
Analysis of MIR202* expression was carried out using the qRT-PCR polyadenylation method [34] . Polyadenylation reactions contained 1 lg of total RNA (8 ll), 0.25 ll (150 U) of Yeast Poly(A) Polymerase (PAP; catalog no. 74225; USB Corporation), 4 ll 53 PAP buffer and 1 ll of 10-nM rATP (Stratagene) and NF water (Promega) in a final volume of 20 ll. Reactions were incubated at 378C for 30 min and then 958C for 5 min and stored at À208C. First-strand cDNA synthesis was performed using Superscript III (Superscript III First-Strand Synthesis Supermix; Invitrogen). Annealing reactions contained 4 ll of polyadenylated total RNA, 3 ll of modified oligo-dT primer (miR-PTA [34] ) at 25 mM, and 1 ll of annealing buffer mix, incubated at 658C for 5 min and cooled on ice. First-strand cDNA synthesis reactions were carried out according to the manufacturer's instructions for oligo-dT-primed RNA. Complementary DNA samples were stored at À208C. All PAP and cDNA synthesis incubations were carried out in a thermal cycler (MasterCycler S; Eppendorf).
Quantitative analysis was performed using StepOnePlus real-time PCR system (Machine and Software; Applied Biosystems), with universal reverse primer PAM-URP to recognize miR-PTA sequence and control or MIR202*-specific forward primers. Chicken U6 small-nuclear RNA (U6) was used as the reference control. Reaction mixes contained 2 ll cDNA diluted 1:50 in NFwater, 10 ll SYBR Green PCR Master Mix (Applied Biosystems), 0.8 ll of each primer (final concentration 200nM), and NFwater to 20-ll final volume. All samples were analyzed in triplicate in 96-well MicroAmp PCR plates (Applied Biosystems). Cycle settings were 948C, 10 min; 948C, 15 sec; and 608C, 1 min (40 cycles). Melt curve was 958C, 15 sec; 608C, 1 min; ramp 0.38C/sec; 958C, 15 sec (one cycle). The delta-delta Ct method [35] was used for relative expression analysis. Melt curve analysis was performed for all reactions using StepOnePlus software (v2.0; Applied Biosystems) with default settings. Single-product amplification was verified by gel electrophoresis of end-point products, using 1.5% TAE Agarose gels. Statistical comparisons of MIR202* expression from qRT-PCR were conducted using the Student t-test (Prism5; GraphPad Software Inc.).
Primers and Probes
All primers, unless otherwise stated, were obtained from Geneworks. The miR-PTA primer was synthesized with HPLC purification, and all other primers synthesized using standard PCR-grade, desalted purification. Primers used for sex-marker gene qRT-PCR were FOXL2 left 5
0 (Sigma Proligo). UPL probes used for sex-marker gene qRT-PCR were FOXL2 #24; DMRT1 #59; SOX9 #61; CYP19A1 (aromatase) #165; and HPRT #38 (Roche Applied Science). Sequences of primers used for miRNA qRT-PCR were miR-PTA 5 Sigma and miRCURY LNA probes were 3 0 -labeled with 3 0 digoxigenin (DIG) in 100 pmol aliquots, according to the manufacturer's instructions (Roche DIG Oligonucleotide 3 0 -End Labeling Kit, 2nd generation, Roche Applied Sciences; see also Banister et al. [16] ). Probes were labeled 1 day before hybridization, stored at À208C, and thawed on ice immediately prior to use. Equal amounts of 3 0 -DIG-labeled Sigma and miRCURY LNA probes were mixed for use in WISH hybridization (both probes can detect MIR202* at the same hybridization temperature, but the miRCURY probe has higher sensitivity because of double DIG labeling). A mixture of probes was used given the number of tissues to analyze by WISH and because limited amounts of miRCURY probe were available.
RESULTS
According to our previous studies, MIR202* is expressed in a male-biased manner at E6.5 and E9.5 in embryonic chicken gonads. Therefore, MIR202* may be involved in regulating testicular development [16] . To understand whether this sexually dimorphic expression is due to MIR202* upregulation in male gonads or to down-regulation in female gonads, we first quantified MIR202* expression changes during sexual differentiation using qRT-PCR. MIR202* expression was analyzed using qRT-PCR in male and female gonads at E5.5, E6.5, and E9.5 ( Fig. 1) . At E5.5 and E6.5, MIR202* expression was not significantly different between male and female gonads but was significantly higher in male versus female gonads at E9.5 ( Fig. 1, P , 0.001) . Comparing between stages, MIR202* expression increased in both sexes between E5.5 and E6.5 (Fig. 1) . Between E6.5 and E9.5, MIR202* expression was specifically increased in male gonads. In the chicken, E6.5 represents the onset of morphological sexual differentiation. Therefore, these results confirmed the previous finding that up-regulation of MIR202* occurs specifically in male gonads from the onset of testicular differentiation.
Having confirmed the MIR202* expression profile, we next sought to demonstrate that up-regulation of MIR202* was associated with the onset of testicular differentiation in an experimental model. We hypothesised that MIR202* expression should be up-regulated when testicular differentiation is induced and down-regulated when testicular differentiation is inhibited.To address this, in ovo estrogen modulation was used to induce gonadal sex reversal in male and female embryonic gonads. To disrupt testis development and induce feminization of male gonads, embryos were treated with estradiol-17b (E2) at E4.5. To disrupt ovary development and induce masculinization of female gonads, embryos were treated at E3.5 with Fadrozole, a chemical AI that blocks endogenous estrogen synthesis. The effects on MIR202* expression were then examined at E9.5.
Disruption of Gonadal Sex Differentiation by Estrogen Modulation
To confirm that testis and ovary development were successfully disrupted by estrogen modulation, gonadal morphology and histology were compared between gonads from control and E2-or AI-treated embryos at E9.5 (Fig. 2) . The E9.5 time point was chosen for analysis, as MIR202* expression levels and testicular and ovarian morphology are normally distinct at this stage [16] . Control male gonads   FIG. 2 . Morphology and expression of gonadal sex markers in E9.5 gonads following estrogen modulation. A) Urogenital morphology and marker expression in control male (ZZ) and female (ZW) gonads. In males, PGCs express CVH and localize to testis cords (i), which also contain Sertoli cells expressing DMRT1 (iii). Aromatase is not expressed in male gonads (ii). Female left gonads have asymmetric ovary development and express aromatase in the medulla (v, m), and germs cells localize in the outer ovarian cortex (iv, c). DMRT1 is expressed at a low level in female gonads (vi). B) Urogenital morphology and marker expression in E2-treated male (ZZ) and female (ZW) gonads. Male E2-treated gonads show feminization of left gonadal cortex, and aromatase expression is induced. C) Urogenital morphology and marker expression in AI-treated male (ZZ) and female (ZW) gonads. Results shown for controls are representative of both control treatments (95% ethanol for E2 experiments and PBS for AI experiments). Green fluorescence indicates expression of sex markers: CVH (i,iv), aromatase (CYP19A1, ii,v), and DMRT1 (iii,vi). Red fluorescence shows fibronectin, which marks the extracellular matrix. In whole-mount urogenital systems, gonads are outlined in black; R ¼ right gonad; L ¼ left gonad. Marker expression is shown for left gonads only. White broken lines separate cortex (c) and medulla (m). Scale bars: whole mount ¼ 1 mm (32.5 magnification); sections ¼ 100 lm (3200 magnification).
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displayed normal bilateral testis development at E9.5 ( Fig. 2A,  ZZ) . Testes appeared symmetrical in size and cylindrical in shape and tapered in diameter at the anterior and posterior ends. Left and right male gonads made up a single layer of cortical epithelium surrounding medullary testis cords. Testis cords were distinguished by a lack of fibronectin staining and localization of PGCs expressing the germ cell marker CVH (official gene name: DEAD [Asp-Glu-Ala-Asp] box polypeptide 4, or DDX4; Fig. 2A, i) . DMRT1-expressing Sertoli cells were also present in the testis cords ( Fig. 2A, iii) . In line with existing reports [8, 10, 36] , the estrogen-synthesizing enzyme aromatase was not expressed in control male gonads ( Fig. 2A,  ii) . Control female gonads displayed normal asymmetric ovary development at E9.5, where the left gonad was larger and flatter in appearance than the right gonad ( Fig. 2A, ZW) . Ovarian cortex development was evident in the left ovary of control female embryos, characterized by the presence of CVH-positive PGCs (Fig. 2A, iv) . Low levels of DMRT1 expression were also detected in the ovary (Fig. 2A, vi) . Aromatase was expressed in the medulla of female gonads ( Fig. 2A, v) .
In contrast to controls, E2-treated male (ZZ) gonads analyzed at E9.5 had increased asymmetry, similar to that seen in control females (Fig. 2B, ZZ) . The left gonads of E2-treated male embryos showed development of an ovarian-like cortex, evidenced by the cortical localization of CVH-positive PGCs (Fig. 2B, I ). PGCs were also localized in the medulla of left male E2-treated gonads in what appeared to be disorganized testis cords (Fig. 2B, i) . In these gonads, DMRT1 was expressed both in the disorganized testis cords in the medulla and in the ovarian-like cortex (Fig. 2B, iii) . Aromatase expression was induced in the medulla of male E2-treated left gonads but at a lower level than that observed in control female gonads (Fig. 2B, ii, ''m'' ). The morphology, PGC localization and DMRT1 and aromatase expression levels were not significantly altered in E2-treated female gonads compared to controls (Fig. 2B, ZW, iv-vi) . These results indicated that estrogen treatment was able to disrupt testis differentiation and partially feminize male gonads.
Treatment with AI did not affect male (ZZ) gonadal development but resulted in masculinization of female (ZW) gonads. This was evident from an increase in left-right gonadal symmetry (Fig. 2C ). Left and right female AI-treated gonads were thin and elongated, similar to the morphology of control male gonads (Fig. 2C, ZW) . The left gonads of female AItreated embryos also had reduced cortical development (Fig.  2C, iv-vi) . Some CVH-positive PGCs were present in the residual cortex, but most were relocalized in a testis cord-like pattern in the medulla (Fig. 2C, iv) . Aromatase expression was reduced in female AI-treated gonads compared to controls (Fig.  2C, v) . Conversely, expression of DMRT1 was up-regulated in testis cord-like structures in the medulla of female AI-treated gonads (Fig. 2C, vi) . These results indicated that blocking Embryos were treated with E2 at E4.5 and AI at E3.5 (black bars). Controls (gray bars) for estrogen (E2) were injected with 95% ethanol (E2). Controls for AI were injected with PBS. Expression levels were normalized to HPRT reference control and are shown as fold difference relative to either control male (DMRT1 and SOX9) or control female (CYP19A1/aromatase and FOXL2). Error bars show standard error of the mean (SEM) from at least three biological replicates in each group. Statistical significance shown by asterisks: *P , 0.05, **P , 0.01, ***P , 0.001.
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endogenous estrogen synthesis was able to disrupt ovarian differentiation and partially masculinize female gonads.
Changes in the Expression of Testis-and Ovary-Associated Genes Following Estrogen Manipulation
Quantitative RT-PCR was used to analyze the expression of known genetic markers of testis and ovary differentiation.
During normal testicular development, DMRT1 and SOX9 are up-regulated in male gonads, while FOXL2 and CYP19A1 (aromatase) are up-regulated in female gonads during ovarian development. As expected, control male gonads from the AI and E2 experiments expressed both DMRT1 and SOX9 (Fig. 3 , C and D, male), while aromatase mRNA was not detected (Fig.  3A, male) , and FOXL2 levels were negilgible (Fig. 3B, male) . However, in male E2-treated gonads, aromatase expression was induced, and FOXL2 expression was significantly upregulated (Fig. 3, A and B, P , 0.01, E2) . In contrast, DMRT1 and SOX9 expression levels were significantly reduced in E2- 
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27 treated male gonads ( Fig. 3C; P , 0.01; Fig. 3D, P , 0.001,  E2) . The expression of all four genes was not significantly altered in female E2-treated gonads versus controls (Fig. 3,  E2) . Together, these results confirmed that ovarian-like gene expression was present in partially feminized male gonads following estrogen treatment.
As expected, control female gonads in AI and E2 experiments showed expression of CYP19A1 (aromatase) and FOXL2 (Fig. 3, A and B) but had lower levels of DMRT1 expression compared to control males, and expression of SOX9 was negligible (Fig. 3, C and B) . Female AI-treated gonads had significantly reduced levels of CYP19A1 (aromatase) and FOXL2 expression (Fig. 3A, P , 0.001; Fig. 3B , P , 0.001, AI), while DMRT1 and SOX9 expression levels were elevated (Fig. 3C, P , 0.01; Fig. 3D, P , 0.05, AI) . The levels of all four genes were not significantly different between control and AI-treated male gonads (Fig. 3, AI) . These results confirmed that testis-associated gene expression was present in partially masculinized female gonads following the inhibition of estrogen synthesis.
Misregulation of MIR202* Expression Following Estrogen Modulation
Having confirmed that estrogen modulation affects both morphological and molecular signatures of embryonic testis and ovary development, we analyzed MIR202* expression in E2-and AI-treated gonads using WISH and qRT-PCR (Figs. 4  and 5 ). As expected, both WISH and qRT-PCR analyses showed elevated MIR202* expression in male versus female control gonads at E9.5 (Figs. 4 and 5) . WISH analysis showed that MIR202* expression was reduced in male E2-treated gonads with feminized morphology (Fig. 4A, asterisks, n ¼ 7) . This was also confirmed by qRT-PCR. MIR202* expression was approximately 3.5-fold lower in E2-treated versus control male gonads (Fig. 4B, MIR202*) . In the WISH analysis, MIR202* expression levels appeared similar between female E2-treated gonads versus controls (Fig. 4A, n ¼ 13) . However, qRT-PCR analysis showed that MIR202* expression was also reduced in E2-treated female gonads versus control female gonads (Fig. 4B) . Therefore, these results indicated that MIR202* expression is reduced in response to estrogen treatment in both male and female embryonic gonads.
Using WISH analysis, female AI-treated gonads with masculinized morphology showed increased MIR202* expression compared to female controls (Fig. 5A, asterisks, n ¼ 15) . This was also confirmed by qRT-PCR analysis, where MIR202* expression was 2-fold up-regulated in AI-treated versus control female gonads (Fig. 5B) . Both WISH and qRT-PCR analyses indicated no significant difference in MIR202* expression between control and AI-treated male gonads (Fig. 5,  A and B) .
To confirm that altered MIR202* expression was a specific response to estrogen modulation and not due to estrogen mediated regulation of miRNA biogenesis in general, the expression of a nonsexually dimorphic miRNA, MIR107, was also measured in control, E2-, and AI-treated gonads. MIR107 did not show sexually dimorphic expression in control E9.5 gonads (Fig. 4B, MIR107 ). MIR107 expression levels were also not significantly different between male or female gonads following either E2 or AI treatment (Figs. 4 and 5, MIR107) . These results demonstrated that estrogen modulation specifically affected sexually dimorphic MIR202* expression in the embryonic gonads. Taken together with the results of the morphological and molecular analyses, these findings confirm that up-regulation of MIR202* expression coincides with testicular differentiation.
DISCUSSION
Tissue-specific miRNA expression patterns during embryonic development may reflect specialized functions for miRNAs in organogenesis [37] . Understanding how these expression patterns are regulated may provide insight into the functions of tissue-specific miRNAs. Our previous studies suggested that MIR202* expression, being male biased in embryonic chicken gonads, is regulated in a sexually dimorphic manner during sexual differentiation [16] . Here, we have confirmed that from E6.5, MIR202* expression is specifically up-regulated in male gonads but remains low in female gonads (Fig. 1) .
MIR202* expresion has not been reported in the embryonic gonads of other vertebrates. However, MIR202* homologues (also known as miR-202-5p) show enriched expression in the adult or postnatal testes of several other vertebrates, including mice: postnatal [27, 38] and adult [26] , humans [39] , Xenopus laevis [40] , and Tasmanian devil (an Australian marsupial) [41] . This shows that testis-enriched MIR202* expression is generally conserved among mammalian and nonmammalian vertebrates. Our study, however, is the first to demonstrate that MIR202* is specifically up-regulated during testicular differentiation using an experimental system. We could redirect MIR202* expression toward female levels in feminized male gonads treated with estrogen and enhance MIR202* expression in masculinized female gonads treated with an AI. Based on these findings, we conclude that MIR202* up-regulation is a reliable marker of testicular differentiation in the chicken embryo.
Changes in gonadal morphology and the expression of known testis-and ovary-associated genes are known to occur following estrogen modulation of gonadal differentiation [6, [12] [13] [14] [15] 32] . The reduction of MIR202* expression in estrogentreated versus control male E9.5 gonads correlated with morphological and histological changes characteristic of ovarian differentiation, namely, an increase in gonadal asymmetry and the development of an ovarian-like cortex containing relocalized PGCs in the left gonad (Fig. 2) . Altered expression of DMRT1, SOX9, FOXL2, and CYP19A1 (aromatase) toward an ovary-associated profile also occurred in male estrogen-treated gonads. Therefore, this provides experimental evidence to confirm that low levels of MIR202* expression are associated with ovarian differentiation.
In conjunction with increased MIR202* expression, AItreated female versus control E9.5 gonads showed signs of testicular differentiation, including enhanced bilateral symmetry and the formation of medullary testis cord-like structures containing PGCs (Fig. 2) . Increased levels of DMRT1 and SOX9 expression and reduced expression of CYP19A1 (aromatase) and FOXL2 in these gonads also demonstrated evidence of masculinized gonadal development at the molecular level. Hence, up-regulation of MIR202* expression occurs during testiscular differentiation. The expression of a nonsexually dimorphic miRNA, MIR107 [16] , was unchanged in estrogen-or AI-treated gonads (Figs. 4B and 5B), further confirming that the observed changes in MIR202* expression in AI-and estrogen-treated gonads were a specific response to altered sexual differentiation. Together, these findings confirm that MIR202* expression levels in embryonic chicken gonads are 28 BANNISTER ET AL. differentially regulated during testicular versus ovarian differentiation.
In female gonads, estrogen is synthesized in the medulla by aromatase [8, 9, 36] and activates estrogen receptor 1, ESR1 (also known as ERa), in the cortical epithelium to promote ovarian differentiation [8, 31, 36, 42] . Estrogen treatment resulted in a decline in MIR202* expression in both male and female gonads (Fig. 4B) . Therefore, we considered the possibility that estrogen signaling itself may act to suppress MIR202* expression in embryonic chicken gonads. Intuitively, this is likely to involve an indirect pathway given that MIR202* is expressed primarily in the medulla of male and female gonads [16] , while ESR1 is activated primarily in the cortical epithelium as ovarian differentiation proceeds [8, 31, 36] .
However, exogenous estrogen treatment creates an artificial environment for gonadal differentiation. Therefore, it could be argued that the down-regulation observed in female E2-treated gonads does not reflect the normal pathway of MIR202* regulation in ovarian differentiation. If negative regulation of MIR202* is normally mediated by estrogen signaling, MIR202* expression in female gonads would be expected to decrease as estrogen levels increase during ovarian differentiation. Our data show that this is not the case. MIR202* expression does not decrease in female gonads between E6.5 and E9.5 ( Fig. 1) , suggesting that negative regulation by estrogen signaling is not primarily responsible for the low level of MIR202* expression seen in female gonads. Therefore, we favor the conclusion that male-biased MIR202* expression is established primarily by male-specific up-regulation during testicular differentiation.
In birds, DMRT1 promotes testicular differentiation in a dosage-dependent manner [3] and is expressed in a male-biased manner from E4.5 on [5] . SOX9 is a conserved testisdetermining gene and is up-regulated in a male-specific manner from E6.0 on [43] [44] [45] . Up-regulation of MIR202* in male gonads follows the onset of testicular differentiation at E6.5 ( Fig. 1) and therefore must occur downstream of DMRT1 and SOX9 up-regulation. MIR202* expression levels in E2-and AI-treated gonads are also altered in the same direction as DMRT1 and SOX9, confirming that MIR202* up-regulation is characteristic of testicular differentiation. MIR202* expression is restricted to the testis cords in male gonads at E6.5 andE9.5 [16] , which is similar to the localization of known or postulated testis-determining genes, including DMRT1 [3, 32] and SOX9 [44, 45] . Therefore, we believe that MIR202* expression is likely to be regulated by the testis-determining pathway. Confirming this will require further studies to demonstrate a direct relationship between MIR202* and DMRT1, SOX9, or other male-specific genes, such as anti-Mullerian hormone [44, 46] . We are currently working to characterize the primary transcript and promoter sequences of MIR202* to address this need.
The function of MIR202* is currently unknown. We predict that miRNAs that act to promote sexual differentiation should show sexually dimorphic expression in the embryonic gonads prior to E6.5. Given that MIR202* expression levels are similar between male and female gonads at E5.5 and are not significantly dimorphic at E6.5, MIR202* is up-regulated as a consequence of testicular differentiation and therefore is unlikely to be involved in initiating testicular differentiation. Based on this profile, we propose that MIR202* may play a role in maintaining testicular development after differentiation is initiated. Our laboratory is currently using overexpression and knockdown approaches to identify testis-specific target genes and to investigate the function of MIR202* in the embryonic chicken testes.
Studies of MIR202* expression at posthatch and adult stages of chicken testicular development are also warranted given a recent study of testicular miRNA expression in Xenopus. Michalack and colleages recently reported that Xenopus MIR202* (xtr-miR-202-5p) is down-regulated in the testes of sterile X. laevis/X. mullerei male hybrids versus those of normal fertile X. laevis males [40] . Therefore, changes in testicular MIR202* expression levels correlate with altered fertility levels in adult male frogs. Whether this indicates a wider role for MIR202* in spermatogenesis remains to be shown.
In summary, MIR202* expression is specifically upregulated in male embryonic chicken gonads from E6.5 on. Using estrogen modulation, we have demonstrated that sexual differentiation accounts for the male-biased MIR202* expression profile seen in endogenous gonads. Low levels of MIR202* expression correlate with ovarian differentiation, and up-regulation of MIR202* is associated with testicular differentiation. Furthermore, changes in MIR202* expression induced by estrogen modulation occur in the same direction as known testis-associated genes DMRT1 and SOX9. From these findings, we conclude that MIR202* up-regulation is a marker of testicular differentiation in the chicken embryo.
